Targets › LHRH
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Nov 2027.
[Gonadoliberin-1]: Hypothalamic decapeptide hormone that functions as the master regulator of the hypothalamic-pituitary-gonadal axis. Released in a pulsatile manner from hypothalamic neuron terminals into the hypophyseal portal circulation, it acts on pituitary gonadotrope cells by binding to and activating its cognate G protein-coupled receptor GNRHR, thereby stimulating the synthesis and secretion of the…. (UniProt, P01148)
Open in Phaseline: the race on LHRH, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Jonsson Comprehensive Cancer Center | Luteinizing hormone-releasing hormone agonist or gonadotropin-releasing hormone Androgen deprivation via LHRH/GnRH agonist or antagonist combined with androgen receptor a | LHRH, GNRH | Phase 2 | PSA Level Greater Than 0.03 | Nov 2027 |
PSA Level Greater Than 0.03 (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.